Azacitidine V2 4.14

AZACITIDINE
An option for patients who are not eligible for haematopoietic stem cell transplantation, with the following conditions:
1. Intermediate-2 or high risk myelodysplastic syndrome
2. Chronic myelomonocytic leukaemia with 10-29% marrow blasts without myeloproliferative disorder
3. AML with 20-30% blasts and multilineage dysplasia
NICE approved March 2011
Drugs/Dosage:
The licensed azacitidine scheduling of daily administration for 7 consecutive days cannot be
followed locally due to the logistical issues of preparing and administering the weekend
doses. In the absence of any proven superior alternative dosing or scheduling, the 2
unlicensed options given below allow for clinician preference across the region:
Schedule 1:
Azacitidine
(25mg/ml)
100mg/m2
s/c bolus
once daily on Days 1 to 5

(5 doses in total)
Schedule 2:
Azacitidine
(25mg/ml)
75mg/m2
s/c bolus
once daily on Days 1 to 5, and Day 8

and Day 9
(i.e. 2 day break over weekend, with 7
doses in total sometimes referred to
as 5+2 schedule)
Administration:
The azacitidine suspension should be prepared immediately before use and administered
within 45 minutes. Alternatively, if it is reconstituted in advance of administration, it should be
stored in a refrigerator for a maximum of 8 hours. The syringe(s) filled with reconstituted
suspension should then be allowed up to a maximum of 30 minutes prior to administration to
reach a temperature of approximately 20C 25C.
or
The contents of the dosing syringe must be re-suspended immediately prior to

administration. To re-suspend, vigorously roll the syringe between the palms until a uniform,
cloudy suspension is achieved. The product should be discarded if it contains large
particles or agglomerates.
Inject subcutaneously using a 25 gauge needle into the upper arm, thigh or abdomen. The
needle should not be purged prior to injection, in order to reduce the incidence of local
injection site reactions.
Doses greater than 4 ml (100mg) should be divided equally between 2 separate syringes
and injected into two separate sites. Injection sites should be rotated. New injections should
be given at least 2.5 cm from the previous site and never into areas where the site is tender,
bruised, red, or hardened.
Other Drugs:
Allopurinol 300mg po od (review after 4 weeks)

Itraconazole liquid 200mg bd as antifungal prophylaxis (if tolerated), for patients with
baseline cytopenia or persistent neutropenia, continued until haematological improvement
Hydrocortisone cream 1%, for topical application to injection site if there is inflammation, rash
or pruritis following the injections
Reason for Update: antiemetics updated ; general review

Version: 2
Supersedes: Version 1
Prepared by: S Taylor
Approved by Chair of Network TSSG: Dr A Laurie

Date: 28.4.14
Review date: May 2016
Checked by: C Tucker
Page 1 of 3
Frequency:
Every 28 days
treat for a minimum of 6 cycles; continue as long as there is patient benefit, or until disease
progression
Main Toxicities:
myelosuppression;
Anti- emetics:
highly emetic: ondansetron 8mg po to be taken 1 2 hours before each azacitidine injection,
plus oral domperidone or metoclopramide as required
Regular
Investigations:
FBC
U&Es
LFTs
Serum bicarbonate
injection site reactions; ovarian failure; infertility
Day 1, weekly during nadir, and as indicated

Day 1
Day 1
Day 1
Dose Modifications
Haematological
Toxicity:
Cycle 1: There are no dose modifications for myelosuppression

Cycle 2 onwards:
Patients without reduced baseline blood counts (i.e. WBC > 3.0 x 109/l, neutrophils >
1.5 x 109/l, and platelets > 75 x 109/l prior to the first treatment)
If haematological toxicity neutrophils < 1.0 x 109/L or platelets < 50 x 109/L at any time - is
observed following azacitidine, the next cycle should be delayed until the platelet and
neutrophil counts have recovered*. If recovery* is achieved within 14 days, no dose
adjustment is necessary. However, if recovery has not been achieved within 14 days, give
50% azacitidine dose once recovery has occurred. Following dose modification, the cycle
duration should return to 28 days.
*Recovery = current counts nadir count + (0.5 x [Baseline count Nadir count])
Patients with reduced baseline blood counts (i.e. WBC < 3.0 x 109/l, neutrophils < 1.5 x
109/l or platelets < 75 x 109/l prior to the first treatment)
Following azacitidine treatment, if the decrease in WBC, neutrophils or platelets from that
prior to treatment is < 50 %, or > 50 % but with an improvement in any cell line
differentiation, the next cycle should not be delayed and no dose adjustment made.
If the decrease in WBC, neutrophils or platelets is > 50 % from that prior to treatment, with
no improvement in cell line differentiation, the next cycle should be delayed until the platelet
and neutrophil counts have recovered. If recovery* is achieved within 14 days, no dose
adjustment is necessary.
However, if recovery* has not been achieved within 14 days, bone marrow cellularity should
be determined. If the bone marrow cellularity is > 50 %, no dose adjustments should be
made.

Version: 2

Date: 28.4.14
Page 2 of 3
If bone marrow cellularity is 50 %, treatment should be delayed and the dose reduced
according to the following table:
Bone marrow cellularity
% dose in next cycle if recovery is not achieved within 14 days

Recovery*
21 days
Recovery* > 21 days
15 50 %
100 %
50 %
< 15 %
100 %
33 %
*Recovery = counts nadir count + (0.5 x [Baseline count Nadir count])

Following dose modification, the cycle duration should return to 28 days.
Renal Impairment:
Patients with renal impairment should be closely monitored for toxicity as azacitidine and its
metabolites are primarily renally excreted. However, no formal studies have been carried out
in patients with impaired renal function, and no specific starting dose modifications are
recommended.
If unexplained fall in serum bicarbonate to < 20mmol/l, give 50% azacitidine dose on next
cycle.
If serum creatinine becomes elevated to 2 times baseline value, the next cycles should be
delayed until serum creatinine returns to normal, then give 50% azacitidine dose on the next
cycle.
Hepatic Impairment:
No formal studies have been carried out in patients with hepatic impairment. Monitor
carefully if azacitidine is used in patients with severe liver impairment, and adjust doses
according to haematological values.
Patient Information:
Macmillan leaflet for Azacitidine
References:
Silverman, LR et al; JCO 2002; 20 (10): 2429 -2440

Silverman, LR et al; JCO 2006; 24 (24): 3895-3903
Garcia, R et al; Spanish Azacitidine Compassionate Use Registry; Proceedings from ASH
2009; Abstract 2773 and poster
Haq, B; JCO; ASCO Proceedings 2006; 24 (18S): Abstract #16532 (5 day schedule)
Pierdomenico, F; Proceedings of the 15th Congress of the European Hematology
Association 2010; Abstract #1402 (5 day schedule)

Version: 2

Date: 28.4.14
Page 3 of 3

Azacitidine V2 4.14

Uploaded by

Copyright:

Available Formats

Azacitidine V2 4.14

Uploaded by

Document Information

Original Description:

Original Title

Copyright

Available Formats

Share this document

Share or Embed Document

Sharing Options

Did you find this document useful?

Is this content inappropriate?

Copyright:

Available Formats

Azacitidine V2 4.14

Uploaded by

Copyright:

Available Formats

AZACITIDINE

once daily on Days 1 to 5

once daily on Days 1 to 5, and Day 8

The contents of the dosing syringe must be re-suspended immediately prior to

Allopurinol 300mg po od (review after 4 weeks)

Reason for Update: antiemetics updated ; general review

Approved by Chair of Network TSSG: Dr A Laurie

injection site reactions; ovarian failure; infertility

Day 1, weekly during nadir, and as indicated

Cycle 1: There are no dose modifications for myelosuppression

Reason for Update: antiemetics updated ; general review

Approved by Chair of Network TSSG: Dr A Laurie

% dose in next cycle if recovery is not achieved within 14 days

Recovery* > 21 days

*Recovery = counts nadir count + (0.5 x [Baseline count Nadir count])

Macmillan leaflet for Azacitidine

Silverman, LR et al; JCO 2002; 20 (10): 2429 -2440

Reason for Update: antiemetics updated ; general review

Approved by Chair of Network TSSG: Dr A Laurie

You might also like